Shanghai Allist Pharmaceuticals (688578) Q3 2025 earnings summary

Executive summary

• Achieved Q3 revenue of RMB 1.36 billion, up 42.03% year-over-year; net profit attributable to shareholders reached RMB 564 million, up 38.77% year-over-year.

• Nine-month revenue totaled RMB 3.73 billion, up 47.35% year-over-year; net profit attributable to shareholders was RMB 1.62 billion, up 52.01% year-over-year.

• Core product sales, especially Vumetinib tablets, drove significant revenue growth and expanded patient reach.

• Enhanced commercialization and marketing strategies increased market penetration and competitive strength.

• RET inhibitor Pralsetinib (Puji Hua®) received NMPA approval for domestic production, expected to boost supply chain resilience from 2026.

Financial highlights

• Q3 operating income: RMB 1.36 billion (+42.03% YoY); nine-month operating income: RMB 3.73 billion (+47.35% YoY).

• Q3 net profit attributable to shareholders: RMB 564 million (+38.77% YoY); nine-month: RMB 1.62 billion (+52.01% YoY).

• Q3 basic and diluted EPS: RMB 1.25 (+38.89% YoY); nine-month EPS: RMB 3.59 (+52.12% YoY).

• Operating cash flow for nine months: RMB 1.73 billion (+39.94% YoY).

• R&D investment for nine months: RMB 421 million (+15.37% YoY); Q3 R&D investment decreased due to prior year milestone payments.

Outlook and guidance

• Pralsetinib’s transition to domestic production in 2026 expected to enhance supply flexibility and benefit more RET-positive patients.

• Continued focus on expanding indications and market share for Vumetinib and other pipeline products.